Clearside Biomedical, Inc.
CLSDNASDAQHealthcare
$0.41
+$0.00(+0.00%)
Market Cap$2145948
P/E Ratio—
52W High$17.1
52W Low$0.31
Clearside Biomedical, Inc. (CLSD) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CLSD · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.66M | $8.23M | $1.33M | $29.57M | $7.89M |
| Cost of Revenue | $0.15M | $0.35M | $0.20M | $0.00M | $0.00M |
| Gross Profit | $1.51M | $7.87M | $1.12M | $29.57M | $7.89M |
| Gross Margin %(computed) | 91.05% | 95.68% | 84.63% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $18.59M | $20.85M | $19.63M | $18.54M | $15.07M |
| G&A Expenses | $11.81M | $11.87M | $11.77M | $11.66M | $10.76M |
| Total Operating Expenses | $30.40M | $32.72M | $31.40M | $30.20M | $25.83M |
| Operating Income | ($28.88M) | ($24.84M) | ($30.28M) | ($0.63M) | ($17.93M) |
| Operating Margin %(computed) | — | -302.02% | — | -2.12% | -227.20% |
| Interest Income | $1.46M | $1.72M | $0.67M | $0.00M | $0.34M |
| Interest Expense | $9.78M | $9.36M | $3.34M | $0.00M | $0.34M |
| Income Before Tax | ($34.35M) | ($32.48M) | ($32.95M) | $0.38M | ($18.21M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($34.35M) | ($32.48M) | ($32.95M) | $0.38M | ($18.21M) |
| Net Margin %(computed) | — | -394.91% | — | 1.27% | -230.68% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-7.05 | $-7.95 | $-8.25 | $0.10 | $-5.85 |
| Wtd Avg Shares | 4.92M | 4.12M | 4.01M | 3.90M | 3.10M |
| EBITDA | ($24.35M) | ($23.06M) | ($29.46M) | $0.55M | ($17.70M) |
| EBITDA Margin %(computed) | — | -280.31% | — | 1.87% | -224.16% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Clearside Biomedical, Inc. data
About Clearside Biomedical, Inc. (CLSD) Income Statement
Clearside Biomedical, Inc. (CLSD) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, CLSD reported revenue of $0.00B, gross profit of $0.00B (gross margin 91.05%), and net income of ($0.03B) — a net profit margin of -2064.42%.
Frequently asked questions
CLSD · 4 questionsClearside Biomedical, Inc. (CLSD) reported revenue of $0.00B for 2024, down 79.8% year-over-year.
CLSD revenueCLSD salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08